48,830
edits
(→Malignant tumours: wikify) |
m (→IHC: wikify) |
||
Line 609: | Line 609: | ||
*Androgen receptor +ve. | *Androgen receptor +ve. | ||
*BRST2 (GCDFP-15) +ve. | *BRST2 (GCDFP-15) +ve. | ||
*HER2 +ve ~21%; use of trastuzumab (Herceptin) not systematically studied. | *HER2 +ve ~21%; use of [[trastuzumab]] (Herceptin) not systematically studied. | ||
Curiosity: | Curiosity: |
edits